What is SMHGF?
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
SMHGF · Verdict
Solid reward · moderate risk
SMHGF stands out on cash flow and profitability, but watch the valuation signal.
Based on 88% data coverage
SMHGF · Verdict
9% free-cash-flow margin
11% net margin · 12% ROE
Current ratio 2.00
Below average
Model-based scoring. For information only — not financial advice.
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 5.07B, and a P/E ratio of 39.2x.
The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.